申请人:Divi's Laboratories Limited
公开号:EP3812371A1
公开(公告)日:2021-04-28
A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising Hofmann rearrangement of (S)-3-(2-(chloroamino)-2-oxoethyl) hexanoic acid, followed by cyclization resulting in (R)-4-propyl-pyrrolidin-2-one which on condensation with bromo butyric acid or ester followed by reaction with ammonia results in Brivaracetam.
提供了一种制备抗惊厥药物 Brivaracetam 的工艺,包括 (S)-3-(2-(氯氨基)-2-氧代乙基) 己酸的霍夫曼重排,然后环化生成 (R)-4-丙基-吡咯烷-2-酮,与溴丁酸或酯缩合后与氨反应生成 Brivaracetam。